M

Mayinglong Pharmaceutical Group Co Ltd
SSE:600993

Watchlist Manager
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Watchlist
Price: 26.19 CNY -0.53% Market Closed
Market Cap: 11.3B CNY
Have any thoughts about
Mayinglong Pharmaceutical Group Co Ltd?
Write Note

Mayinglong Pharmaceutical Group Co Ltd
Other Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Mayinglong Pharmaceutical Group Co Ltd
Other Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
M
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Other Current Assets
ÂĄ202.4m
CAGR 3-Years
-30%
CAGR 5-Years
-21%
CAGR 10-Years
6%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Other Current Assets
ÂĄ129.8m
CAGR 3-Years
30%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Other Current Assets
ÂĄ357.3m
CAGR 3-Years
8%
CAGR 5-Years
15%
CAGR 10-Years
28%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Other Current Assets
ÂĄ1.8B
CAGR 3-Years
13%
CAGR 5-Years
23%
CAGR 10-Years
24%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Other Current Assets
ÂĄ1B
CAGR 3-Years
-29%
CAGR 5-Years
-9%
CAGR 10-Years
12%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Other Current Assets
ÂĄ70.3m
CAGR 3-Years
58%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Mayinglong Pharmaceutical Group Co Ltd
Glance View

Market Cap
11.3B CNY
Industry
Pharmaceuticals

In the corridors of China's pharmaceutical industry, Mayinglong Pharmaceutical Group Co Ltd stands out with its roots deeply embedded in history while its branches stretch ambitiously into the future. Founded in 1582 during the Ming Dynasty, this firm has garnered a reputation for its innovative approach to traditional Chinese medicine. The company's evolution from an apothecary serving local communities to a publicly traded enterprise mirrors the dynamic growth of China itself. As the world became increasingly captivated by holistic health solutions, Mayinglong capitalized on its heritage of time-tested remedies, turning ancient formulations into modern products. Their flagship product, Mayinglong Hemorrhoid Ointment, is a renowned success, both domestically and internationally, symbolizing the company's unique ability to blend ancient wisdom with contemporary health needs. Mayinglong's business model thrives on a well-balanced portfolio that includes not only traditional Chinese medicines but also a growing pipeline of innovative pharmaceuticals and healthcare products. Leveraging state-of-the-art technology in their R&D centers, they develop new drugs and therapies that align with both modern health trends and the regulatory demands of global markets. The group's revenue streams are diversified across multiple segments, including over-the-counter products, prescription medications, and personal care items. With a vast distribution network both in China and abroad, Mayinglong benefits from scale and brand recognition. Their strategy is a testament to the harmonious merger of tradition and modernity, driving profitability through a deep understanding of consumer needs paired with scientific innovation.

Intrinsic Value
31.89 CNY
Undervaluation 18%
Intrinsic Value
Price
M

See Also

What is Mayinglong Pharmaceutical Group Co Ltd's Other Current Assets?
Other Current Assets
202.4m CNY

Based on the financial report for Sep 30, 2024, Mayinglong Pharmaceutical Group Co Ltd's Other Current Assets amounts to 202.4m CNY.

What is Mayinglong Pharmaceutical Group Co Ltd's Other Current Assets growth rate?
Other Current Assets CAGR 10Y
6%

Over the last year, the Other Current Assets growth was -33%. The average annual Other Current Assets growth rates for Mayinglong Pharmaceutical Group Co Ltd have been -30% over the past three years , -21% over the past five years , and 6% over the past ten years .

Back to Top